Literature DB >> 22139415

Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Enrique Calvo1, F Javier Pastor, Valentina Salas, Emilio Mayayo, Josep Guarro.   

Abstract

The efficacy of the combination of anidulafungin (AFG) at 1 mg/kg plus voriconazole (VRC) at 25 mg/kg was evaluated in a murine model of disseminated infection by Aspergillus flavus using three isolates previously tested in vitro. All the combinations showed indifferent in vitro interaction with the exception of one, which showed synergy. In general, the combined treatment prolonged the survival and reduced the fungal load in comparison with AFG alone, and only in a few cases, it improved the results of the VRC monotherapy. The combination of the two drugs and VRC alone reduced the galactomannan levels in serum in comparison with the control group.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22139415     DOI： 10.1007/s11046-011-9507-6

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  32 in total

1.  Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.

Authors:  A Thomas; V Korb; R Guillemain; T Caruba; V Boussaud; E Billaud; P Prognon; D Begué; B Sabatier
Journal:  J Clin Pharm Ther       Date:  2010-02       Impact factor: 2.512

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 3.  [In vitro activity of the echinocandins. How should it be evaluated?].

Authors:  Francisco Javier Pastor; Josep Guarro
Journal:  Rev Iberoam Micol       Date:  2005-09       Impact factor: 1.044

4.  Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.

Authors:  James A Dowell; Jennifer Schranz; Alice Baruch; Grover Foster
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

Review 5.  The safety of anidulafungin.

Authors:  José A Vazquez
Journal:  Expert Opin Drug Saf       Date:  2006-11       Impact factor: 4.250

6.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

Review 7.  Pharmacokinetics/pharmacodynamics of echinocandins.

Authors:  U Theuretzbacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-14       Impact factor: 3.267

8.  Successful antifungal combination therapy with voriconazole and caspofungin.

Authors:  Friedhelm Schuster; Christian Moelter; Irene Schmid; Ulrike B Graubner; Birgit Kammer; Bernd H Belohradsky; Monika Führer
Journal:  Pediatr Blood Cancer       Date:  2005-06-15       Impact factor: 3.167

9.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758
View more
  6 in total

1.  In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

2.  Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies.

Authors:  Ming Zhang; Wen-Kui Sun; Ting Wu; Fei Chen; Xiao-Yong Xu; Xin Su; Yi Shi
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

3.  Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Deanna A Sutton; Annette W Fothergill; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

5.  Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.

Authors:  Ming Zhang; Xin Su; Wen-Kui Sun; Fei Chen; Xiao-Yong Xu; Yi Shi
Journal:  Mycopathologia       Date:  2013-12-06       Impact factor: 2.574

Review 6.  Review on Current Status of Echinocandins Use.

Authors:  Martyna Mroczyńska; Anna Brillowska-Dąbrowska
Journal:  Antibiotics (Basel)       Date:  2020-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.